Qurient Co. Ltd (KQ:115180) — Market Cap & Net Worth
Market Cap & Net Worth: Qurient Co. Ltd (115180)
Qurient Co. Ltd (KQ:115180) has a market capitalization of $540.41 Million (₩797.43 Billion) as of September 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #11947 globally and #324 in its home market, demonstrating a -1.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qurient Co. Ltd's stock price ₩21400.00 by its total outstanding shares 37263098 (37.26 Million). Also see 115180 total asset value for a full breakdown of the balance sheet.
Qurient Co. Ltd Market Cap History: 2025 to 2026
Qurient Co. Ltd's market capitalization history from 2025 to 2026. Data shows growth from $763.89 Million to $540.41 Million (0.00% CAGR). Also see Qurient Co. Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Qurient Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$235.78 Billion | 0.23% | #75 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$235.78 Billion | 0.23% | #75 of 1384 |
Weight: Qurient Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Qurient Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qurient Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 115180 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.11x
Qurient Co. Ltd's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $763.89 Million | $6.98 Billion | -$30.05 Billion | 0.11x | N/A |
Competitor Companies of 115180 by Market Capitalization
Companies near Qurient Co. Ltd in the global market cap rankings as of September 19, 2026. Review 115180 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Qurient Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Qurient Co. Ltd Historical Marketcap From 2025 to 2026
Between 2025 and today, Qurient Co. Ltd's market cap moved from $763.89 Million to $ 540.41 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩540.41 Million | -29.26% |
| 2025 | ₩763.89 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Qurient Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $540.41 Million USD |
| MoneyControl | $540.41 Million USD |
| MarketWatch | $540.41 Million USD |
| marketcap.company | $540.41 Million USD |
| Reuters | $540.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more